The Global Pathogen Center for Pathogen Research and Human Health to broaden understanding of emerging pathogens – ranging from Zika virus to SARS-CoV-2 (which causes COVID-19) – and to expedite critically needed treatments and vaccines.
Vaxess Technologies celebrates the grand opening of their 3,600 square feet pilot GMP manufacturing facility on Monday.
Watson-Marlow is pleased to announce that construction will start in October 2021, on a new state-of-the-art manufacturing facility in the United States, with first production due in late 2022.
GISTs arise from specialized nerve cells found in the walls of the gastrointestinal tract. One or more mutations in the DNA of one of these cells may lead to the development of GIST.
FDA takes efforts to improve quality of compounded drugs from outsourcing facilities through collaboration and education as part of new Center of Excellence. Compounded drugs can serve an important role in meeting patients’ medical needs that cannot be met by an FDA-approved drug.
Millstone Medical Outsourcing has officially broken ground on its new 56,385 square foot facility in Fall River, MA. The MA headquarter campus will now hold a total of 124,367 square feet of production space, including its existing 15,000 square feet of class 10,000/ISO7-rated cleanroom space for medical device packaging operations.
Pepscan announced that its GMP production capacity has doubled. Pepscan is an all-in-one partner in peptides, building on 25 years of experience in advancing and applying peptide expertise to facilitate clients in the development and production of peptides.
GE Healthcare Life Sciences and Germfree are joining expertise to develop a fully integrated, expandable manufacturing solution for emerging biotherapeutics, including gene therapy.
VetStem Biopharma, a veterinary and human regenerative medicine CRO, used its extensive experience, FDA master files, and database of veterinary stem cell therapy to secure FDA approval of a human IND for stem cell therapy in patients with osteoarthritis. VetStem made the application to FDA on behalf of its subsidiary, Personalized Stem Cells, Inc.
Mile High Labs, a Colorado startup that calls itself the world’s largest manufacturer of products, purchased the plant in Broomfield, Colorado, for about $18.8 million.
Multinational pharmaceutical company GlaxoSmithKlyne (GSK) launched two new pharmaceutical manufacturing facilities and an expanded production building at its Jurong site. According to GSK, the new and expanded sites will allow the faster production of drugs and Active Pharmaceutical Ingredients (APIs) for clinical trials.
Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it is investing more than $50 million in its global bioproduction capabilities to provide additional capacity for manufacturing single-use bioprocess container (BPC) systems.